More than malaria: Exploring Babesia, Leishmania and Trypanosoma in sickle cell disease Authors: Chanakya R Bhosale, Zachary L Morcos, Amanda Escudero, Raghavee Neupane, Zaneh Kahook, Genessiss Miranda, Emily Deehan, Randal K Gregg, Anna K Potter Published: 2026 ABSTRACT AbstractVector-borne parasites, such as species of Babesia, Trypanosoma, and Leishmania, are emerging and re-emerging causes of infectious diseases that contribute substantially to global morbidity and mortality. Epidemiological shifts, such as expansion of arthropod vector ranges, increased international travel, and transfusion-associated transmission, have amplified their public health impact. A key distinction among these parasites is their localization within the host. Babesia spp. infect erythrocytes, Leishmania spp. reside within macrophages, and Trypanosoma cruzi invades muscle cells, whereas Trypanosoma brucei remains extracellular within the bloodstream and lymphatics. These differences influence immune evasion, disease progression, and treatment response. Sickle cell disease (SCD) is a hereditary hemoglobinopathy characterized by abnormal erythrocytes, chronic hemolysis, vaso-occlusion, and progressive organ damage, which may significantly alter host susceptibility to parasitic infections. While interactions between SCD and malaria-causing Plasmodium spp. are well established, less is known about its impact on infections caused by Babesia spp., Trypanosoma spp., and Leishmania spp. This narrative review synthesizes current evidence on the relationship between SCD and these parasites, focusing on pathophysiology, immune responses, clinical manifestations, and management strategies. Differences in intracellular versus extracellular localization are examined to better understand their effects on disease severity and treatment outcomes. Improved understanding of these interactions may inform targeted screening, novel therapeutic/management approaches, and transfusion safety strategies (especially those at increased risk for transfusion-transmitted infections), while highlighting critical gaps for future research.Keywords: Sickle cell disease, Babesia, Leishmania, Trypanosoma, Vector-borne parasites, Host-parasite interactions, Immune dysregulation, Hemolysis, Transfusion-transmitted infections Introduction Parasitic vector-borne infections continue to contribute substantially to global infectious disease burden and mortality across diverse human populations. Many of these organisms, including members of the phylum Apicomplexa (e.g. Babesia spp.) and the phylum Euglenozoa (Leishmania spp. and Trypanosoma spp.), are emerging or re-emerging causes of parasitic infections worldwide. Transmission typically occurs via the salivary glands of hematophagous arthropods such as ticks, sand flies, and tsetse flies, or through exposure to the feces or urine of infected triatomine bugs (Karshima et al., 2022; Wang et al., 2025). In addition to vector-borne transmission, these parasites may also be transmitted through blood transfusions, organ transplantation, congenital routes, and oral ingestion of parasites (Esch and Petersen, 2013). Environmental changes, including shifts in temperature, vegetation, water quality, precipitation, and vector distribution, further influence parasite prevalence and facilitate spread into non-endemic regions (Short et al., 2017). Together, these factors highlight the importance of continued investigation into the epidemiology, prevention, and management of these infections. Genetic blood disorders, such as sickle cell disease (SCD), play a significant role in determining susceptibility to and outcomes of blood-borne parasitic infections. SCD results from biallelic mutations in the HBB gene, producing abnormal hemoglobin S (HbSS), that leads to erythrocyte distortion, hemolysis, vaso-occlusion, and immune dysfunction, compared with normal adult hemoglobin (HbAA) (NIH, 2021; Mangla et al., 2023; Taher et al., 2025). In contrast, individuals with sickle cell trait (HbAS) inherit only one abnormal B-globin allele and are typically asymptomatic under clinical conditions. These pathophysiological features contribute to chronic inflammation, oxidative stress, and impaired immune responses, increasing susceptibility to parasitic, bacterial, and viral infections (Li et al., 2024; Taher et al., 2025). The relationship between SCD and parasitic infections is complex and influenced by parasite biology, host immune response, and underlying disease mechanisms. It is well established that individuals with sickle cell trait have partial protection against malaria causing, erythrocyte-invading parasites, such as Plasmodium falciparum, illustrating how hemoglobin variants can influence parasite susceptibility (Aneni et al., 2013; Mangano et al., 2015). Proposed mechanisms include sickling of infected erythrocytes, enhanced clearance through hemolysis, modulation of host immunity, and induction of heme oxygenase-1 (Archer et al., 2018). However, SCD is not solely an erythrocyte disorder. It is also characterized by systemic immune dysregulation, chronic inflammation, endothelial dysfunction, and altered macrophage activity (Kavanagh et al., 2022). These broader host alterations extend beyond red blood cells and may significantly influence susceptibility to and outcomes of infections caused by parasites that do not directly invade erythrocytes. In contrast to Plasmodium spp., vector-borne parasites such as Babesia spp., Leishmania spp., and Trypanosoma spp. interact with host systems beyond erythrocytes, including macrophages, endothelial cells, and circulating immune pathways. As such, the systemic features of SCD may be critical determinants of disease course in these infections. Despite increasing recognition of these infections, their interaction with SCD remains underexplored in both endemic and non-endemic settings. This review investigates how SCD influences susceptibility, pathophysiology, and clinical outcomes of emerging, re-emerging, or lesser-known vector-borne parasites, specifically Babesia spp., Leishmania spp., and Trypanosoma spp. It emphasizes how parasite localization within the host shapes mechanisms of infection, disease severity, and treatment response. By examining parasites with distinct cellular pathways, this review provides a unified framework for understanding how both erythrocyte-specific and systemic features of SCD influence host-parasite interactions. These insights will help increase awareness and may guide the development of more effective, tailored prevention and treatment strategies for high-risk populations worldwide. Methodology A structured narrative literature review was conducted using PubMed, Web of Science, and Google Scholar to consolidate current information on the relationship between SCD and blood-borne parasitic infections. The literature search for relevant articles in the SCD context sections was performed using combinations of keywords and Medical Subject Headings (MeSH), where applicable, including: “sickle cell disease” OR “sickle cell anemia” AND “babesiosis” OR “Babesia”; “leishmaniasis” OR “Leishmania”; and “trypanosomiasis” OR “Trypanosoma” OR “African sleeping sickness” OR “Chagas disease”. Boolean operators were used to refine searches across PubMed and Web of Science, while simplified keyword combinations were used in Google Scholar. Primary research articles were eligible for inclusion if they were peer-reviewed, available in English, and published between January 2010 and January 2025. Articles published before 2010, or those that supported our discussion were included selectively when they provided essential background information or strengthened discussion of management and treatment. A supplementary search was also conducted through January 2026 to capture any recent changes to treatment guidelines and newly published clinical reports. Eligible studies included original research articles, case reports, case series, and review articles addressing the relationship between SCD and blood-borne parasitic infections, including pathophysiology, immune responses, clinical manifestations, and management strategies. Exclusion criteria included studies published before 2010 unless used for background context, conference abstracts without full texts, editorials, and commentaries. Studies not directly relevant to the interaction between SCD and blood-borne parasites, as well as those focused solely on non-parasitic infections or unrelated hematological conditions, were also excluded. The quality of included studies was assessed based on study design, sample size, methodological style, and relevance to SCD specific outcomes. Greater emphasis was placed on primary research articles and well-characterized clinical reports, while review articles were used primarily to provide background context and support broader thematic interpretation. Various tables were also created to organize and highlight comparative host-parasite interactions with SCD and also showcase the currently available case studies available on Babesia spp., Leishmania spp., and Trypanosoma spp. infections with SCD in humans as discussed in the article. Comparative host-parasite interactions in sickle cell disease Table 1 provides a summary and comparative overview of host-parasite interactions among Babesia, Leishmania, and Trypanosoma species in context of sickle cell disease (SCD). Although these vector-borne species differ substantially in their life cycles, tissue tropism, and pathogenesis mechanisms, all can interact with host immune and hematological pathways that are altered in SCD. The table highlights key similarities in parasite localization, immune responses, clinical manifestations, and potential consequences for disease severity. Together, these comparisons show that parasite-SCD interactions can be pathogen-specific and extend beyond the erythrocyte-focused locus often associated with malaria or Plasmodium spp. Understanding these mechanisms may help explain differences in susceptibility, clinical presentation, and outcomes for patients with SCD exposed to different parasitic vector-borne infections. Table 1Comparative host-parasite interactions of Babesia spp., Leishmania spp., and Trypanosoma spp. in sickle cell disease.Table 1OrganismPrimary host targetLocalizationMajor immune evasion pathogenic mechanismsSCD specific interactionsMajor clinical concern in SCDKey citationsBabesia spp.ErythrocytesIntracellularErythrocyte invasion, hemolysis, cytokine activation, splenic clearance evasionHbSS erythrocytes impair parasite development through oxidative stress, membrane instability, shortened erythrocyte lifespan, and enhanced clearanceSevere hemolysis, transfusion-transmitted infection, delayed diagnosisYi et al. (2018); Karkoska et al. (2018); Cursino-Santos et al. (2019); Beri et al. (2023)Leishmania spp.MacrophagesIntracellularComplement evasion, silent macrophage entry, Th2 polarization, HO-1 inductionChronic hemolysis and HO-1 upregulation may impair intracellular parasite clearance and promote persistencePancytopenia, hepatosplenomegaly, HLH, vaso-occlusive crises during treatmentLuz et al. (2012); Garcerant et al. (2012); Balandya et al. (2016); Dhayhi et al. (2017)Trypanosoma cruziCardiac and smooth muscle cellsIntracellularPersistent inflammation, immune-mediated tissue injuryChronic inflammation and endothelial dysfunction may worsen vaso-occlusion and cardiomyopathy riskChagas cardiomyopathy, transfusion-transmitted infectionSousa et al. (2014); Bocchi et al. (2017); Crowder et al. (2022)Trypanosoma bruceiBloodstream and lymphaticsExtracellularAntigenic variation through VSGsImmune dysregulation and anemia may exacerbate hematological complications in SCDCNS involvement, anemia, immune exhaustionPinger et al. (2017); Neves et al. (2021); Franco et al. (2024)Abbreviations: SCD, sickle cell disease; VSG, variant surface glycoprotein; CNS, central nervous system; HLH, hemophagocytic lymphohystiocytosis; HO-1, heme oxygenase-1; Th2, T-helper type 2 cells. Comparative host-parasite interactions of Babesia spp., Leishmania spp., and Trypanosoma spp. in sickle cell disease. Abbreviations: SCD, sickle cell disease; VSG, variant surface glycoprotein; CNS, central nervous system; HLH, hemophagocytic lymphohystiocytosis; HO-1, heme oxygenase-1; Th2, T-helper type 2 cells. Babesiosis and sickle cell disease Overview and immunology Babesia spp. are blood-borne apicomplexan parasites that infect both animals and humans, causing babesiosis. Transmission occurs primarily through the bite of infected ixodid ticks (most commonly Ixodes spp.), although infection may also occur via blood transfusion or, rarely, through congenital transmission. Babesia spp. have become one of the most common parasites transmitted through blood transfusions in the USA (Moritz et al., 2016; Krause et al., 2021; Drews et al., 2023). While over 100 Babesia species have been identified, only a few are known to infect humans, including Babesia microti, Babesia divergens, and Babesia duncani, though other emerging species may also have the potential to infect humans (Vannier and Krause, 2012; Young et al., 2019; Krause et al., 2021). Babesia microti is the predominant disease-causing species worldwide and is endemic to the northeastern and midwestern USA as well as parts of China (Kumar et al., 2021; Swanson et al., 2023). Sporadic cases of babesiosis in the US Pacific Northwest are linked to B. duncani (Swei et al., 2019). The incidence and epidemiology of babesiosis in the USA have shifted substantially in the last decade, with CDC surveillance data from 2011 to 2019 showing rising incidence across 8 of 10 reporting states, increasing recognition in previously non-endemic areas (Swanson et al., 2023). This change could be recognized by changing vector distribution and transfusion associated cases. In Europe, most cases are attributed to B. divergens, particularly in splenectomized patients (Vannier and Krause, 2012). Clinical symptoms typically develop 1–4 weeks following exposure and include fever, chills, diaphoresis, fatigue, and myalgias (Vannier and Krause, 2012). Although many infections remain asymptomatic, severe disease, including hemolytic anemia and multi-organ dysfunction can occur in high-risk populations such as immunocompromised, asplenic, and elderly individuals (Heller, 2024). Following inoculation, Babesia spp. sporozoites enter the bloodstream and attach to erythrocyte glycosaminoglycans and sialoglycoproteins (Vannier and Krause, 2012; Rabah et al., 2022). They differentiate into trophozoites, which undergo asexual budding into merozoites, eventually lysing host erythrocytes (Vannier and Krause, 2012). This process further contributes to hemolytic anemia, fever, jaundice, hemoglobinuria, hemoglobinemia, and renal insufficiency. Unlike Plasmodium spp., Babesia spp. replicate asynchronously, which may account for less extensive hemolysis compared to malaria (Vannier et al., 2015; Djokic et al., 2021). Host immunity involves macrophages, tumor necrosis factor-α, interleukin-12, B-lymphocyte-derived antibodies, T-lymphocyte cytokines such as interferon-γ, and complement activation (Vannier et al., 2015). Parasite glycosylphosphatidylinositol (GPI) anchors expressed on infected erythrocytes stimulate pro-inflammatory cytokine release. Excessive cytokine and nitric oxide production can lead to systemic inflammatory responses, sepsis-like manifestations, and multi-organ failure (Cornillot et al., 2012; Debierre-Grockiego et al., 2019). As infected erythrocytes pass through the spleen, they are cleared by macrophages, making splenectomized individuals particularly susceptible to severe, high-level parasitemia (Vannier and Krause, 2012). Other high-risk groups include patients with HIV, individuals over 50 years of age, neonates, and immunocompromised patients (Mareedu et al., 2017). These interactions highlight the importance of understanding how Babesia spp. behave in patients with sickle cell disease (SCD), where altered erythrocyte physiology may significantly influence disease progression. Babesia spp. in the context of sickle cell disease Cursino-Santos et al. (2019) demonstrated that Babesia divergens can invade HbSS, HbAS, and HbAA erythrocytes. However, parasites within HbSS erythrocytes exhibited abnormal development, impaired egress, and reduced ability to infect new cells. In contrast to Plasmodium spp., HbAS erythrocytes supported parasite invasion and replication similarly to HbAA cells (Cursino-Santos et al., 2019). Notably, parasites originating in HbSS erythrocytes failed to recover even after transfer to HbAA cells, suggesting irreversible disruption during early development (Beri et al., 2023). These in vitro findings are further supported by in vivo murine studies examining Babesia infection in the setting of SCD. In a murine SCD model, Yi et al. (2018) observed significantly lower parasitemia in HbSS mice compared to HbAA and HbAS controls. While parasitemia peaked around day seven in HbAA and HbAS mice, HbSS mice demonstrated a slower increase. Despite these differences, all groups cleared infection by day 21 and survived. Importantly, although HbSS mice exhibited 4–5-fold lower parasitemia, they mounted comparable immune responses, suggesting an intrinsic erythrocyte-related mechanism limiting parasite replication (Yi et al., 2018). Several mechanisms may explain impaired Babesia growth in HbSS erythrocytes, including increased oxidative stress from hemoglobin polymerization, membrane instability, reduced erythrocyte lifespan, and enhanced splenic clearance (Beri et al., 2023). Similar to malaria, babesiosis may also induce a “bystander hemolysis” effect, in which uninfected erythrocytes are destroyed (Woolley et al., 2017). In HbSS patients, this effect is amplified due to baseline membrane fragility and oxidative stress, creating an unfavorable environment for parasite survival while simultaneously worsening hemolysis (Beri et al., 2023). Despite this apparent partial protective effect, Babesia infection poses significant risks in SCD. Both conditions independently cause hemolysis, and co-infection can rapidly exacerbate anemia and lead to severe complications (Karkoska et al., 2018). Yi et al. (2018) demonstrated increased hemolysis in infected HbSS mice, evidenced by reduced hematocrit and increased hemoglobinuria. Patients with SCD who require chronic transfusions are at particularly high risk for transfusion-transmitted babesiosis (Karkoska et al., 2018; Costa et al., 2023). Several case reports have documented delayed diagnosis due to overlapping clinical features with delayed hemolytic transfusion reactions (Karkoska et al., 2018). For example, Karkoska et al. (2018) described two transfusion-associated cases in SCD, while Costa et al. (2023) reported a third case in an SCD patient on chronic red cell exchange therapy who acquired B. microti infection from an unscreened unit (Table 2). Overall, although Babesia spp. seroprevalence has been reported to be high in endemic areas, no studies to our knowledge have specifically evaluated seroprevalence in SCD patients, despite their increased transfusion exposure and enlarging risk factors (Johnston et al., 2022; Karshima et al., 2022). These diagnostic challenges strengthen the need for heightened clinical suspicion and improved screening protocols in both endemic and non-endemic settings (Costa et al., 2023; Drews et al., 2023). Table 2Highlighted clinical cases of Babesia spp. infections in patients with sickle cell disease.Table 2OrganismCountryYearPatient’s sex/ageSCD genotypeInitial presentationKey findingsManagementOutcomeCitationB. microtiUSA20171 F (21 years)HbSS (chronic transfusions)Fever and acute pain following transfusionRelapsing parasitemiapRBC transfusion; quinine/clindamycin (discontinued); azithromycin/atovaquone; later doxycycline; prednisoneRelapse after initial therapy; required prolonged treatmentKarkoska et al. (2018)B. microtiUSA20171 M (11 years)HbSβ thalassemia (chronic transfusions)Fever, acute pain, history of hemolysisRecurrent parasitemia following initial clearanceClindamycin/quinine azithromycin/atovaquone; methylprednisolone for presumed AIHA; prednisone taper; prolonged therapy with azithromycin/atovaquone/doxycyclineParasitemia recurrence; symptom-free > 12 months after extended therapyKarkoska et al. (2018)B. microtiUSA20231 M (30 years)HbSS (chronic transfusions)Fever, chills, neck pain, photophobia, headache, fatigue, loss of appetite, 2 months post-RICEPeripheral smear: intraerythrocytic parasites (< 0.5% parasitemia); Increased IgM/IgG titers; NAT-positive; no tick exposure; transfusion history (65 units/6 months); donor trace → seropositive asymptomatic donorAzithromycin + atovaquone (10-day course)Symptom resolution with treatmentCosta et al. (2023)Abbreviations: SCD, sickle cell disease; pRBC, packed red blood cell; AIHA, autoimmune hemolytic anemia; RICE, red-blood cell exchange; F, female; M, male. Highlighted clinical cases of Babesia spp. infections in patients with sickle cell disease. Abbreviations: SCD, sickle cell disease; pRBC, packed red blood cell; AIHA, autoimmune hemolytic anemia; RICE, red-blood cell exchange; F, female; M, male. Management and treatment According to the Infectious Diseases Society of America (IDSA) 2020 Clinical Practice Guidelines, first-line treatment for babesiosis consists of a 7–10-day course of atovaquone plus azithromycin, with clindamycin plus quinine as an alternative regimen (Krause et al., 2021). In immunocompetent individuals, symptoms typically resolve and parasitemia clears within this timeframe (Krause et al., 2021). However, fatigue and PCR positivity may persist for several weeks, and relapse is uncommon (Krause et al., 2021). In high-risk patients, including those with SCD or significant immunosuppression, prolonged therapy is often required. This is particularly relevant in patients with SCD, who often have functional asplenia and impaired immune clearance, predisposing them to higher parasite burdens, delayed clearance, and increased risk of relapse (Karkoska et al., 2018; Beri et al., 2023). In high-risk individuals, long-term antimicrobial therapy with blood monitoring is recommended, usually for six weeks. Therapy is maintained until parasitemia decreases to <4%, followed by weekly monitoring, and continued until two consecutive weeks of negative smears are achieved (Krause et al., 2021). Close monitoring of hematological parameters, including hemoglobin levels, reticulocyte count, lactate dehydrogenase, and bilirubin, is essential in this population to distinguish infection-related hemolysis from underlying SCD complications such as vaso-occlusive crisis or aplastic episodes (Karkoska et al., 2018; Kavanagh et al., 2022; Feugray et al., 2023). Severe cases may require supportive interventions such as antipyretics, vasopressors, blood transfusions, exchange transfusion, mechanical ventilation, or dialysis (Sanchez et al., 2016; Krause et al., 2021). In patients with SCD, there should be a lower threshold for transfusion or exchange transfusion due to the risk of rapid hemolysis and clinical decompensation (Karkoska et al., 2018; Costa et al., 2023). In 2018, the FDA licensed DNA PCR and antibody assays for screening blood donors for B. microti, followed by the release of final guidance in 2019 recommending year-round regional Babesia screening of blood donations in endemic areas (Moritz et al., 2016; Villatoro and Karp, 2019). Current screening strategies rely primarily on nucleic acid testing (NAT), including the two FDA-approved blood donor screening assays: a transcription-mediated amplification (TMA) detecting Babesia ribosomal RNA, and a polymerase chain reaction (PCR)-based assay detecting Babesia DNA (Stanley et al., 2021; Tonnetti et al., 2022). Donors with reactive NAT results are deferred, and blood products from positive donations are not released for transfusion (Tonnetti et al., 2019). Despite these advancements, significant gaps in screening remain. In regions without mandated testing, donor-history screening remains the primary safeguard. The risk of transmitting infection from an unscreened donation is approximately 15.6 times greater than from a screened, Babesia-negative unit (Tonnetti et al., 2019), and cases continue to emerge from unscreened donations collected in non-endemic states due to blood product distribution patterns (LeBel et al., 2017; Costa et al., 2023). Interestingly, no cases of transfusion-transmitted babesiosis were reported from screened donations in the first year of implementation, underscoring the effectiveness of NAT-based screening where it has been adopted (Tonnetti et al., 2022). These findings are particularly important for patients with SCD, who frequently require chronic transfusions and therefore remain at disproportionately higher risk for transfusion-transmitted infection. Taken together, babesiosis represents a significant threat to patients with SCD, particularly those requiring chronic transfusions. Data on tick-borne acquired cases, or seroprevalence of Babesia spp. in SCD patients in endemic areas is also lacking, underscoring the need for targeted epidemiological studies in this population. The combination of diagnostic challenges, immune evasion, and exacerbation of hemolysis highlights the need for improved screening protocols, enhanced pathogen-reduction technologies, and increased clinician awareness to optimize outcomes in this vulnerable population (Stramer et al., 2022; Drews et al., 2023). In this context, management must integrate prompt antimicrobial therapy, careful hematological monitoring, and transfusion risk mitigation strategies to effectively address both the babesiosis infectious process and the underlying hematological instability present in SCD. Leishmaniasis and sickle cell disease Overview and immunology Leishmania spp. are protozoan parasites transmitted to humans through the bite of infected female phlebotomine sand flies, causing a spectrum of diseases collectively referred to as leishmaniasis. These parasites are endemic in 99 countries across tropical and subtropical regions, including parts of the southern USA, Central and South America, Africa, and the Middle East (Burza et al., 2018). Leishmaniasis presents in three primary clinical forms: cutaneous (CL), mucocutaneous (ML), and visceral (VL). Cutaneous leishmaniasis is the most common and is characterized by skin lesions, ulcers, and potentially permanent scarring. Although approximately 200,000 cases are reported annually, the true global incidence is estimated to range from 600,000 to 1 million cases (Alvar et al., 2012). Mucocutaneous leishmaniasis can result in destructive mucosal involvement, while visceral leishmaniasis represents the most severe form, presenting with fever, weight loss, hepatosplenomegaly, anemia, and pancytopenia (Burza et al., 2018). Following transmission, Leishmania promastigotes employ multiple strategies to evade host immune defenses. These parasites inhibit formation of the membrane attack complex (C5-C9), thereby avoiding complement-mediated lysis (Verma et al., 2018). This resistance is mediated by surface molecules such as lipophosphoglycan (LPG) and glycoprotein 63 (GP63), which interfere with complement activation and phagocytosis by disrupting C5 convertase formation (Gupta et al., 2013; Pereira-Filho et al., 2023). Rather than triggering an acute inflammatory response, Leishmania parasites use macrophage complement receptor, via complement receptor 3 (CR3), which allows intracellular survival without triggering a robust immune response (Dixit et al., 2021). Additionally, Leishmania spp. modulate host immune signaling by altering chemokine expression and skewing responses toward a non-protective T helper 2 (Th2) phenotype. Upregulation of chemokine ligand 7 (CCL7) promotes recruitment of Th2 cells producing interleukin-4 (IL-4), impairing clearance of intracellular pathogens (Katzman and Fowell, 2008; Poudel et al., 2020). Concurrently, suppression of interferon-γ-inducible protein 10 (IP-10) reduces recruitment and activation of natural killer (NK) and T helper 1 (Th1) cells (Antonia et al., 2021; Howard et al., 2022). This shift toward Th2 dominance weakens IFN-γ-mediated antimicrobial activity, facilitating chronic infection and parasite persistence. Leishmania spp. in the context of sickle cell disease Unlike other blood-borne parasites, Leishmania spp. primarily disrupt macrophage function and immune regulation, a distinction that is particularly relevant in patients with sickle cell disease (SCD). Chronic hemolysis in SCD leads to the release of free heme, which activates Toll-like receptor 4 (TLR4)-mediated inflammation (Belcher et al., 2014). However, free heme also induces heme oxygenase-1 (HO-1), which reduces oxidative stress while simultaneously suppressing pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α), a key mediator of intracellular pathogen clearance. Increased HO-1 activity, driven by both SCD-related hemolysis and Leishmania infection, creates an immunosuppressive environment that favors parasite persistence (Luz et al., 2012; Saha et al., 2019). Additionally, baseline impairment of Th1 responses in SCD further compromises host control, increasing susceptibility to severe manifestations such as hepatosplenomegaly and pancytopenia (Balandya et al., 2016). Although reported cases of Leishmania spp. infection in SCD are limited, available evidence highlights significant diagnostic and therapeutic challenges. Co-infection may precipitate severe complications, including hemophagocytic lymphohistiocytosis (HLH), a hyperinflammatory syndrome characterized by uncontrolled immune activation and cytopenias (Shoman et al., 2018; Shi et al., 2021). One case involved a two-year-old child with SCD presenting with prolonged fever and splenomegaly, later progressing to pancytopenia and hepatosplenomegaly (Dhayhi et al., 2017, Table 3). Initial bone marrow evaluation was unremarkable; however, repeat aspiration revealed Leishmania donovani with associated hemophagocytosis and elevated ferritin levels, consistent with HLH. Treatment with liposomal amphotericin B resulted in clinical and hematological improvement (Aronson et al., 2016; Dhayhi et al., 2017). In another case, a six-year-old child with cutaneous leishmaniasis developed abdominal pain, splenomegaly, and lower extremity pain after initiation of meglumine antimoniate, leading to the diagnosis of previously unrecognized SCD during a vaso-occlusive crisis (Garcerant et al., 2012, Table 3). Pentavalent antimonials disrupt parasite redox balance by targeting trypanothione and glutathione pathways (Wyllie et al., 2004). However, these agents may also impair host glutathione metabolism, increasing oxidative stress in erythrocytes and precipitating hemolysis and vaso-occlusive crises in SCD. Table 3Highlighted clinical cases of Leishmania spp. infections in patients with sickle cell disease.Table 3OrganismCountryYearPatient’s sex/ageSCD genotypeInitial presentationKey findingsManagementOutcomeCitationUnspecified species (cutaneous form)Colombia20121 M (6 years)Diagnosed during the courseChronic ulcerative ear lesions (6 months)Amastigotes identified; later developed abdominal pain, diarrhea, splenomegaly, and sickle cell crisis; SCD diagnosed via sodium metabisulfite test and smearMeglumine antimoniate; ceftriaxone; folic acidRecovery with residual ear scarring; experienced SCCGarcerant et al. (2012)L. donovani (visceral form)Saudi Arabia20171 M (2 years)Not reportedIntermittent fever (2 weeks), progressing to persistent fever, tachycardia, hepatosplenomegalyPancytopenia; poikilocytosis; initial bone marrow negative; repeat bone marrow positive for Leishmania; secondary hemophagocytosis; elevated ferritin (4264 ng/ml)Liposomal amphotericin BClinical improvement: ferritin decreased over 7 monthsDhayhi et al. (2017)Abbreviations: SCD, sickle cell disease; SCC, sickle cell crisis; F, female; M, male. Highlighted clinical cases of Leishmania spp. infections in patients with sickle cell disease. Abbreviations: SCD, sickle cell disease; SCC, sickle cell crisis; F, female; M, male. Clinically, these findings demonstrate that SCD-associated immune dysregulation, oxidative stress, and splenic dysfunction not only increase susceptibility to Leishmania infection but also complicate diagnosis and exacerbate disease severity. Management and treatment Management of Leishmania spp. infection in patients with SCD requires a tailored approach that integrates parasite directed therapy with mitigation of SCD specific complications. Delayed diagnosis is common due to overlapping features such as fever, hepatosplenomegaly, and pancytopenia; therefore, clinicians should maintain a low threshold for repeat diagnostic testing, including bone marrow evaluation, when suspicion for visceral leishmaniasis (VL) persists despite initially negative results (Aronson et al., 2016; Burza et al., 2018). Liposomal amphotericin B remains the preferred first-line therapy for VL due to its efficacy and favorable safety profile, particularly with respect to minimizing oxidative stress and nephrotoxicity (Aronson et al., 2016). In contrast, pentavalent antimonials (e.g. sodium stibogluconate, meglumine antimoniate) should be used with caution in SCD patients, as their disruption of glutathione-dependent redox pathways may exacerbate oxidative stress, precipitate hemolysis, and trigger vaso-occlusive crises (Garcerant et al., 2012). Alternative agents such as miltefosine may be considered in select cases, although patient-specific risks must be carefully evaluated (Sundar et al., 2012; Monge-Maillo and Lopez-Velez, 2015). Supportive care is equally critical and should focus on preventing SCD-related complications during infection and treatment. Adequate hydration, electrolyte management, and early initiation of multimodal analgesia are essential to reduce the risk of vaso-occlusive crises (Kavanagh et al., 2022). Close monitoring of hematological parameters is necessary, as both VL and SCD contribute to anemia and pancytopenia, and transfusion support may be required in severe cases (Debash et al., 2023). Clinicians should also maintain a high index of suspicion for hyperinflammatory complications such as hemophagocytic lymphohistiocytosis (HLH), particularly in patients with persistent fever, cytopenias, and elevated ferritin levels, as early recognition is critical for reducing morbidity (Shi et al., 2021). Given the central role of oxidative stress in both SCD and leishmaniasis, adjunctive strategies aimed at supporting redox balance, such as glutathione precursors (e.g. L-glutamine), may be beneficial, although further evidence is needed (Niihara et al., 2018). Overall, management should be mechanism-driven, balancing effective parasite clearance with prevention of oxidative and inflammatory complications. Early recognition, prompt initiation of appropriate therapy, particularly liposomal amphotericin B, and comprehensive supportive care are essential to optimize outcomes. A multidisciplinary approach with close monitoring for complications such as HLH is critical in this high-risk population. Trypanosomes and sickle cell disease Overview and immunology Trypanosoma cruzi and Trypanosoma brucei are protozoan parasites responsible for Chagas disease (CD) and African trypanosomiasis (sleeping sickness), respectively. Trypanosoma cruzi, the etiological agent of CD, is primarily transmitted through the excreta of triatomine (“kissing”) bugs via bite wounds or mucous membranes (de Sousa et al., 2024). Additional transmission routes include congenital transfer, organ transplantation, oral ingestion of contaminated food or drink, and blood transfusion. Although historically endemic to Latin America, globalization, migration, and vector distribution have expanded the burden of CD to North America and Europe (de Sousa et al., 2024). In contrast, T. brucei is transmitted by the tsetse fly and remains largely confined to sub-Saharan Africa, with T. brucei gambiense causing a chronic form and T. brucei rhodesiense an acute, often fatal illness. In 2021–2022, a total of 802 and 837 cases were reported globally, with 94% caused by T. b. gambiense (Franco et al., 2024). The host immune response to trypanosome infection is complex and contributes significantly to disease pathology. Trypanosoma cruzi infection induces a strong pro-inflammatory response characterized by elevated cytokines such as TNF-α and IFN-γ, which are essential for parasite control but also drive chronic inflammation and tissue damage, particularly in the myocardium and gastrointestinal tract. In a clinical study of 176 patients with chronic CD, inflammatory cytokines including IFN-γ, TNF-α, IL-6, and IL-1β were highest in the cardiac group, while IL-10 expression was associated with better cardiac function (Sousa et al., 2014). Persistent inflammation promotes fibrosis and progressive cardiomyopathy, a hallmark of chronic CD. In contrast, T. brucei evades immune clearance through antigenic variation of variant surface glycoproteins (VSGs), enabling cycles of parasitemia and immune evasion. Full VSG coat replacement requires several days to complete, and parasites undergoing coat replacement are vulnerable to clearance via early IgM antibodies for only a limited time, with IgM losing its ability to mediate trypanosome clearance at unexpectedly early stages of coat replacement based on a critical density threshold (Pinger et al., 2017). This process leads to sustained immune activation with dysregulated cytokine production, including both pro-inflammatory (IFN-γ) and anti-inflammatory (IL-10) signals, contributing to anemia, immune exhaustion, and central nervous system invasion in later stages of disease. Trypanosomes in the context of sickle cell disease The clinical impact of trypanosome infection in individuals with SCD is amplified by overlapping mechanisms of inflammation, hemolysis, and endothelial dysfunction. In SCD, chronic hemolysis leads to nitric oxide depletion and endothelial activation, predisposing patients to vaso-occlusion (Kato et al., 2017). The heightened inflammatory state induced by T. cruzi, driven by TNF-α and IFN-γ, may further exacerbate endothelial dysfunction and promote vaso-occlusive crises, increasing the risk of acute and chronic organ damage (Bocchi et al., 2017). Additionally, anemia in SCD may be worsened by trypanosome-induced alterations in iron metabolism. Trypanosoma brucei infection has been shown to increase hepcidin expression, restricting iron availability and impairing erythropoiesis (Neves et al., 2021). In patients with SCD, who already experience chronic hemolytic anemia, this effect may exacerbate cytopenias and increase transfusion requirements. Repeated transfusions, a common therapeutic intervention in SCD, also introduce a risk of transfusion-transmitted T. cruzi, even in non-endemic regions due to global migration patterns (Nunes et al., 2018; Crowder et al., 2022). Notably, the first documented case of transfusion-transmitted T. cruzi in a child with SCD was reported in Belgium (Blumental et al., 2015; Crowder et al., 2022, Table 4). Table 4Highlighted clinical cases of Trypanosoma spp. infections in patients with sickle cell disease.Table 4OrganismCountryYearPatient’'s sex/ageSCD genotypeInitial presentationKey findingsManagementOutcomeCitationT. cruziBelgium20151 M (7 years)SCD (type not specified)Asymptomatic; transfusion-acquired infectionDetected 8 months post-transfusion via screening; no acute CD symptomsBenznidazole (8 weeks, 5 mg/kg BID); hydroxyurea (held initially)Asymptomatic infection; case highlights need for screeningBlumental et al. (2015)Abbreviations: SCD, sickle cell disease; CD, Chagas disease; BID, twice-a-day; F, female; M, male. Highlighted clinical cases of Trypanosoma spp. infections in patients with sickle cell disease. Abbreviations: SCD, sickle cell disease; CD, Chagas disease; BID, twice-a-day; F, female; M, male. Although other case reports describing clinical outcomes of CD with SCD are absent from our literature search, two Brazilian cohort studies have documented serological evidence of T. cruzi co-infection in SCD populations, representing to our knowledge the only available data on this combination (Neto et al., 2011; Blatyta et al., 2020). Neto et al. (2011) conducted a cross-sectional study of 1415 SCD patients in which CD seropositivity was detected in 40 patients (2.8%), while Blatyta et al. (2020) reported that among 2779 SCD patients, CD seropositivity was detected in only 13 patients (0.5%). Differences in prevalence may reflect the impact of mandatory donor screening implemented in Brazil in the late 1990s (De Paula et al., 2008), but the lack of clinical course documentation likely reflects underdiagnosis and underreporting in areas of high disease burden with SCD, underscoring the need for further studies examining the interaction between these conditions. In contrast to CD, no case reports, cohort studies, or seroprevalence data documenting African trypanosomiasis co-infection in individuals with SCD were identified in our literature search. This gap likely reflects the declining global incidence of human African trypanosomiasis, fewer than 1000 cases reported annually since 2018, with only 802 and 837 cases in 2021, and 2022, respectively (Franco et al., 2024), combined with limited diagnostic infrastructure in endemic regions where SCD prevalence is highest (Esoh et al., 2021). The most notable intersection between SCD and African trypanosomiasis is likely indirect. For example, the protective APOL1 G1/G2 variants, which evolved under selective pressure from T. brucei, are prevalent in populations of African ancestry and predispose individuals, including those with SCD, to complications of chronic kidney disease or sickle cell nephropathy, potentially leading to worsened outcomes (Kormann et al., 2017; Friedman and Pollak, 2020; Esoh et al., 2025). Furthermore, the coexistence of SCD and trypanosome infection may accelerate end-organ complications. For example, chronic inflammation and parasite persistence in T. cruzi infection increase the risk of Chagas cardiomyopathy, which may compound baseline cardiac stress seen in SCD (Nunes et al., 2013; Hammoudi et al., 2020). Similarly, T. brucei-associated central nervous system involvement may exacerbate neurologic vulnerability in SCD patients, who are already at increased risk for stroke (Oluwole et al., 2024). The combined effects of immune dysregulation, chronic inflammation, and impaired pathogen clearance may also reduce the efficacy of anti-parasitic therapy, necessitating individualized and closely monitored treatment strategies. Management and treatment Management of trypanosome infection in patients with SCD requires a multidisciplinary and mechanism-informed approach that prioritizes early detection, prevention, and careful integration of anti-parasitic therapy with SCD-specific supportive care. Preventive strategies are critical, particularly in populations at risk for transfusion-related transmission. Blood products should be routinely screened for T. cruzi in both endemic and high-migration regions (Crowder et al., 2022; de Castro et al., 2025). In T. brucei endemic areas, vector control measures, including insecticide-treated nets and tsetse fly traps, remain essential components of disease prevention (Franco et al., 2024). Prompt initiation of anti-parasitic therapy is essential to reduce parasite burden and limit disease progression. Standard treatment for Chagas disease includes benznidazole or nifurtimox, though both agents carry notable adverse effect profiles, including dermatological reactions, gastrointestinal intolerance, and peripheral neuropathy (Cantey et al., 2021; de Sousa et al., 2024). For African trypanosomiasis, fexinidazole is now recommended as first-line oral therapy for both T. brucei gambiense and T. brucei rhodesiense in patients aged ≥ 6 years weighing ≥ 20 kg, effective across both disease stages (Lejon et al., 2025; Matovu et al., 2025). Nifurtimox-eflornithine combination therapy (NECT) is reserved for severe second-stage gambiense HAT (CSF WBC > 100/μl) and for children < 6 years or weighing < 20 kg (Lejon et al., 2025). In patients with SCD, supportive care plays a critical role in mitigating complications during infection and treatment. Close monitoring for worsening anemia, hemolysis, and vaso-occlusive crises is essential, particularly given the pro-inflammatory and hematological burden of co-infection. Adequate hydration, pain management, and transfusion support should be provided as needed to maintain hemodynamic stability and reduce sickling-related complications (Kavanagh et al., 2022). Clinicians should also maintain vigilance for organ-specific sequelae, including Chagas cardiomyopathy and central nervous system involvement in African trypanosomiasis. Overall, management requires balancing effective parasite clearance with the prevention of exacerbated inflammation, hemolysis, and end-organ damage. Early recognition, individualized therapy, and coordinated multidisciplinary care are essential to optimize outcomes in this vulnerable population. Future directions and research priorities for parasite-sickle cell disease interactions Blood-borne parasites, particularly those within the phylum Apicomplexa (e.g. Babesia spp.), as well as Trypanosoma spp. and Leishmania spp., continue to pose significant public health concerns due to their widespread transmission and association with severe morbidity and mortality. Their interaction with pre-existing hematological conditions such as SCD remains a crucial area of research, as specific mechanisms of disease progression, distinctions between different species within the same genus, immune responses, and treatment standardization are underexplored. As human migration patterns and vector epidemiology continue to influence the spread of parasitic diseases, research must continue to address these challenges. Future studies should focus on (i) Understanding the immunological interactions between SCD and parasitic infections, (ii) Improving screening and prevention strategies for transfusion-transmitted parasites, and (iii) Developing new, effective antiparasitic treatment guidelines that account for the unique pathophysiology of SCD. By addressing these gaps, we can enhance patient outcomes, reduce mortality, and improve management strategies for individuals with SCD who are at increased risk for these parasitic infections. A primary focus should be on understanding host-parasite interactions. Although host-parasite dynamics in SCD have been explored in certain infections, their influence across different parasitic species remains poorly defined. In particular, the impact of HbAS on Babesia spp. infection is underexplored; unlike other parasitic infections, babesiosis does not rely on synchronized erythrocyte lysis, raising uncertainty as to whether HbAS confers a comparable survival advantage (Yi et al., 2018; Beri et al., 2023). More broadly, immune dysregulation in SCD, characterized by chronic inflammation and impaired cell-mediated immunity, may alter host responses to parasitic pathogens. Parasites such as Leishmania spp. actively modulate host immunity by skewing responses toward a Th2 phenotype, potentially exacerbating defective parasite clearance in SCD. Although these interactions have been proposed primarily on mechanistic grounds, clinical validation is lacking, underscoring the need for studies identifying immunological, hematological, and molecular biomarkers that can confirm altered susceptibility and disease progression in the setting of SCD-associated comorbidities. Another key area of focus is understanding the role of blood transfusion in parasite transmission. Blood transfusions, a cornerstone of SCD management, increase the risk of acquiring transfusion-transmitted parasitic infections. Pathogens such as Babesia spp. and T. cruzi are capable of transmission through blood products, yet screening practices remain inconsistent, particularly in non-endemic regions where clinical suspicion is low (Blumental et al., 2015; Yi et al., 2018; Costa et al., 2023). The absence of routine, sensitive screening assays for many of these parasites allows infections to go undetected, delaying diagnosis and contributing to more severe clinical outcomes in hosts with functional immune impairment, such as individuals with SCD. These gaps highlight the need for enhanced surveillance strategies, improved diagnostic testing, and stricter donor screening policies, especially in endemic and high-risk populations. Another area of concern is emerging drug resistance and treatment challenges. Many blood-borne parasites have developed resistance to first-line antiparasitic therapies, complicating disease management in vulnerable populations. Leishmania spp. have evolved resistance to pentavalent antimonials, and Trypanosoma spp. evade therapeutic clearance through antigenic variation (Frimpong et al., 2018; Eirich et al., 2024). These resistance mechanisms limit treatment efficacy and may disproportionately affect immunocompromised individuals, including those with SCD, who are at increased risk for severe and persistent infections. Consequently, there is a pressing need for the development of standardized, broadly effective antiparasitic therapies with improved safety profiles tailored to immunocompromised hosts. Lastly, while this review focuses on selected blood-borne parasites, it is crucial to recognize the broader landscape of infectious diseases that may exacerbate complications in individuals with SCD. Individuals with SCD are predisposed to bacterial and viral co-infections due to chronic hemolysis, functional asplenia, and immune dysregulation, which may worsen the severity of concurrent parasitic infections (Ochocinski et al., 2020). Bacterial pathogens such as Salmonella spp., Klebsiella spp., and Clostridioides difficile occur with increased frequency in SCD and can complicate the clinical course when present alongside parasitic diseases (Ochocinski et al., 2020). In parallel, viral infections, including hepatitis B, hepatitis C, and prolonged SARS-CoV-2 infection (long COVID), are prevalent in regions endemic for parasitic pathogens and exert immunosuppressive effects that may further increase susceptibility to infections such as Leishmania spp. and Trypanosoma spp. (Mitra and Mawson, 2017). These overlapping infectious burdens underscore the need for integrated diagnostic and therapeutic strategies that account for bacterial, viral, and parasitic co-infections in immunocompromised populations. Limitations This review has some methodological limitations that should be considered when interpreting its findings. First, our search was restricted to English-language publications, which may have excluded relevant clinical data published in Spanish, Portuguese, or French from endemic regions in Latin America and sub-Saharan Africa. This is particularly relevant given that Chagas disease research is highly concentrated in Brazil and Latin America, where Brazil alone accounts for over half of all Chagas-related publications (González-Alcaide et al., 2018), whereas African trypanosomiasis research originates largely from West and Central Africa. Published reviews on these diseases have routinely included multilingual searches; for example, prior Lancet Infectious Diseases reviews on Chagas disease and African trypanosomiasis explicitly searched for articles in English, Spanish, Portuguese, and French (Blum et al., 2008; Lescure et al., 2010). While major findings from non-English studies are often captured indirectly through English-language reviews, the possibility of missed case reports or clinical series describing SCD, trypanosome or SCD, Leishmania co-infection cannot be excluded, particularly given the rarity of these co-infections. Secondly, the LILACS database (Latin American and Caribbean Health Sciences Literature), which indexes regional Latin American health sciences journals, was not included in the search strategy. Inclusion of LILACS may have identified additional publications from endemic regions not indexed in PubMed, Web of Science, or Google Scholar. Thirdly, this manuscript was designed as a focused narrative review examining clinically relevant interactions between selected vector-borne protozoan infections and SCD rather than a formal systematic review or meta-analysis. Consequently, studies including human infections (i.e. T. evansi) or infections without direct relevance to SCD were not included, although these topics may warrant further investigation in future reviews. While a structured literature search and predefined inclusion criteria were utilized, PRISMA-style quantitative reporting of study screening and exclusion was not performed. Fourthly, the inclusion of pre-2010 studies for background context, while necessary given the limited literature on SCD parasite co-infection, may introduce some subjectivity in study selection. Additionally, the limited number of case reports, seroprevalence studies, and mechanistic investigations limits the ability to draw definitive conclusions about clinical outcomes, and the quality assessment may not fully capture methodological limitations of individual studies. Finally, the exclusion of conference abstracts may have omitted emerging data, particularly from investigators in endemic regions where full-text publication in indexed journals may be delayed. Despite these limitations, the structured search across three major databases and the inclusion of diverse study designs provide a reasonable foundation for synthesizing current knowledge on this underexplored topic. These limitations also highlight opportunities for future systematic reviews incorporating multilingual searches, regional databases such as LILACS, and formal quality and quantity assessment tools to strengthen the evidence base on SCD parasite co-infection. Conclusions The relationship between SCD and blood-borne parasitic infections is not fully understood, warranting continued study and deeper examination of this complex interaction. Individuals with SCD, due to their functionally immunocompromised state related to splenic dysfunction or immune dysregulation, may have increased susceptibility to parasites such as Babesia spp., Leishmania spp., and Trypanosoma spp. The cases reviewed in this study demonstrate that patients with SCD and concurrent parasitic infections may experience exacerbated symptoms, treatment-related complications, and diagnostic challenges, particularly when symptoms are misattributed to SCD. Furthermore, patients with SCD frequently require blood transfusions, which in many cases have been associated with transmission of parasitic infections. These findings highlight how limitations in diagnosis and prevention can lead to delayed treatment and adverse healthcare outcomes. A deeper understanding of the pathophysiology of both SCD and parasitic infections, and how they interact, is essential for mitigating these risks and reducing their global health burden. Overall, prospective cohort studies and in-field case-based investigations in regions with high parasitic disease burden and SCD prevalence will be critical for validating proposed mechanistic interactions, identifying clinically relevant biomarkers, and informing evidence-based screening and treatment strategies. Improved awareness among healthcare professionals in both endemic and non-endemic areas, along with targeted screening and early detection strategies, is critical to addressing this challenge. These efforts are essential for enhancing preventative measures and optimizing treatment strategies, ultimately improving the quality of care and overall outcomes for individuals with SCD affected by parasitic infections caused by species of Babesia, Leishmania, and Trypanosoma. Ethical approval Not applicable. CRediT authorship contribution statement Chanakya R. Bhosale: Conceptualization, Formal analysis, Validation, Methodology, Data curation, Project administration, Visualization, Writing – original draft, Writing – review & editing. Zachary L. Morcos: Investigation, Writing – original draft, Writing – review & editing. Amanda Escudero: Investigation, Writing – original draft, Writing – review & editing. Raghavee Neupane: Validation, Writing – original draft, Writing – review & editing. Zaneh Kahook: Investigation, Writing – original draft, Writing – review & editing. Genessiss Miranda: Investigation, Writing – original draft, Writing – review & editing. Emily Deehan: Investigation, Writing – original draft, Writing – review & editing. Randal K. Gregg: Conceptualization, Supervision, Validation, Writing – review & editing. Anna K. Potter: Conceptualization, Supervision, Validation, Writing – review & editing. Funding Not applicable. Declaration of competing interests The authors declare that they do not have any competing financial interests, personal relationships, or external funding that could influence the work and data reported in this review paper. Acknowledgements We would like to thank the Student Osteopathic Medical Association (SOMA) for supporting leadership development and collaborative learning through this research review. Data availability The data supporting the body, discussion, and conclusions in this review are included within the article. The Graphical abstract was created in BioRender. (https://BioRender.com/1xvji2y). References Associated Data Data Availability Statement The data supporting the body, discussion, and conclusions in this review are included within the article. The Graphical abstract was created in BioRender. (https://BioRender.com/1xvji2y).